3D InSight™ Mitochondrial Toxicity Testing Service | InSphero

Assess mitochondrial liabilities with advanced, organotypic 3D liver microtissues

3D InSight™ Mitochondrial Toxicity Testing uses a robust and highly predictive two-step assay to combine organotypic 3D liver microtissues with state of the art label-free mitochondrial function analysis on the Seahorse XFe96 Analyzer (Agilent Technologies). The longer in vitro lifespan of 3D InSight™ Human Liver Microtissues enables extended culture and flexible drug exposure times with repeat dosing.

  • Study long-term drug exposure effects with repeat dosing in a highly predictive two-step assay
  • Perform label-free assessment of oxygen consumption rate (OCR) by combining 3D InSight™ Human Liver Microtissues with the Seahorse XFe96 Analyzer
  • Identify mitochondrial liabilities with high sensitivity and specificity in a primary 3D liver model with higher spare respiratory capacity (SRC) than 2D monolayer hepatocyte cultures

Service Description

Slide Enable high-sensitivity mitochondrial liability assessment with a two-step workflow that includes the initial drug exposure phase followed by independent OCR assessment on the Seahorse XFe96 Analyzer using the specialized Seahorse spheroid microplate. Slide Assess SRC in 3D primary human hepatocytes (green) displaying a 4X greater SRC (red-shaded area) than 2D PHH (gray), more closely reflects that of  in vivo liver. (Curves represent means and standard deviations normalized to 1000 cells). Slide Enable mitotoxicity testing in a standardized, metabolically robust 3D model with 4x greater SRC, thus ensuring experimental reproducibility for longitudinal and multi-site studies. (Bioenergetics profile of 6 independent runs of OCR in untreated human liver microtissues: green line indicates mean across replicates; shaded area depicts standard deviations).

Service at a Glance

Download our brochure for details on the standard service protocol, which includes:

  • Phase I: Dose range-finding for cell viability
  • Phase II: OCR analysis on Seahorse XFe96 and cell viability
  • Analysis of compounds regarding mitochondrial liability based on viability and SRC dose response curves
  • Customization: Drug exposure times for Phase II can be customized (up to 14 days). The number and timing of repeat dosings will vary based on the length of drug exposure
Catalog # Description
SP-02-210-01 3D InSight™ Mitochondrial Toxicity Testing

Microtissues and Kits


Request Additional Resources

Brochure: Mitochondrial Toxicity Testing


Poster: Mitochondrial Activity Assessment


Webinar: Understanding Cellular Metabolism of Spheroids Using Extracellular Flux Technology

Find out how you can identify mitochondrial liabilities

with greater confidence.

Get Started